Grant: Strategic Projects - Group
University of British Columbia
$50,000.00
Application of new catalytic technologies in the synthesis of substituted piperazines. New approaches for the synthesis of calcium channel blockers for pain treatment.
EF 2009-10
Résumé
Catalytic methods afford energy efficient routes for the synthesis of complex molecules. Recent developments from a pharmaceutical company in Vancouver, British Columbia, Neuromed, have shown that a family of nitrogen containing cyclic compounds, piperazines, can be used for a novel approach toward the treatment of chronic pain. Chronic pain affects the lives of millions of Canadians and costs the country billions in reduced productivity and increased medical costs. Consequently, new orally available treatments that avoid addictive and sedative side-effects that are common with drugs such as Morphine, are highly sought after. This proposal addresses an alternative, catalytic synthetic approach for the rapid and facile synthesis of this class of piperazine products. The catalysts to be employed for this reaction build carbon-nitrogen bonds with no by-products and are a new class of catalysts that take advantage of the low cost and low toxicity of zirconium metal. The proposed synthetic strategy reduces the number of synthetic steps, which in turn reduces waste-streams while accessing a broad range of piperazines which may display desirable biological activity. Neuromed pharmaceuticals will be involved in screening catalytically prepared compounds for favourable activity. Overall, the impact of this new synthetic approach will improve manufacturing efficiency and flexbility to enhance productivity while reducing energy consumption and environmental impacts in the synthesis of this important class of compounds.
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
365198-2008
Name nom
Schafer, Laurel
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
50000
Program id
STPGP
Program nane en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1043
Committee name en
Strategic Projects Selection Panel - Manufacturing
Committee name fr
Comité de sélection des projets stratégiques - Fabrication
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3607
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Catalysis
Research subject fr
Catalyse
Partie
2
Nb partie
3
Application title
Application of new catalytic technologies in the synthesis of substituted piperazines. New approaches for the synthesis of calcium channel blockers for pain treatment.
Keyword
NA
Application summary
Catalytic methods afford energy efficient routes for the synthesis of complex molecules. Recent developments from a pharmaceutical company in Vancouver, British Columbia, Neuromed, have shown that a family of nitrogen containing cyclic compounds, piperazines, can be used for a novel approach toward the treatment of chronic pain. Chronic pain affects the lives of millions of Canadians and costs the country billions in reduced productivity and increased medical costs. Consequently, new orally available treatments that avoid addictive and sedative side-effects that are common with drugs such as Morphine, are highly sought after. This proposal addresses an alternative, catalytic synthetic approach for the rapid and facile synthesis of this class of piperazine products. The catalysts to be employed for this reaction build carbon-nitrogen bonds with no by-products and are a new class of catalysts that take advantage of the low cost and low toxicity of zirconium metal. The proposed synthetic strategy reduces the number of synthetic steps, which in turn reduces waste-streams while accessing a broad range of piperazines which may display desirable biological activity. Neuromed pharmaceuticals will be involved in screening catalytically prepared compounds for favourable activity. Overall, the impact of this new synthetic approach will improve manufacturing efficiency and flexbility to enhance productivity while reducing energy consumption and environmental impacts in the synthesis of this important class of compounds.